Gedea Biotech
Develops an antibiotic-free, safe and effective treatment of vaginal fungal infections.
- biotechnology
- horizon europe
- dt and ls
- woman founder
- biotech and pharma
- eit ecosystem
- drug development
- eit health
- eit supernovas
- eicfund
- sextech
- european health catapult (eit health)
- investor network (eit health)
- women's health
- investor network 2018 (eit health)
- european health catapult 2018 (eit health)
- gold track (eit health)
- gold track 2019 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | €2.5m | Grant | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 770 % | 511 % | (23 %) | - | - | 122 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (30 %) | (22 %) | (30 %) | - | (35 %) | (132 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Gedea Biotech is a Swedish health company based in Lund, specializing in innovative treatments for women's health issues, particularly vaginal infections. The company has developed a product called pHyph, which is an antibiotic-free treatment for both vaginal fungal infections and bacterial vaginosis. These conditions are common and recurring problems that affect women globally.
Gedea Biotech operates in the healthcare and biotechnology market, focusing on providing effective and sustainable medical solutions. Their primary clients are women suffering from these specific vaginal health issues. The company has made significant strides in securing intellectual property rights, having been granted patents in both Europe and the United States, which are two of the largest healthcare markets. These patents are valid until 2037, providing Gedea Biotech with a substantial competitive advantage.
The business model of Gedea Biotech revolves around the research, development, and commercialization of their proprietary treatments. They conduct clinical trials to validate the effectiveness of their products, with recent trials showing that 82% of subjects were clinically cured of bacterial vaginosis after one week of using pHyph. This high success rate enhances the product's marketability and trust among healthcare providers and patients.
Gedea Biotech generates revenue through the sale of its pHyph treatment. As the product gains regulatory approvals and market acceptance, the company is poised to expand its market reach and increase its sales. Additionally, the company may explore partnerships with healthcare providers and distributors to further enhance its market penetration.
In summary, Gedea Biotech is a forward-thinking company addressing significant medical needs in women's health with innovative, antibiotic-free treatments. Their strong patent portfolio and promising clinical trial results position them well for growth in the global healthcare market.
Keywords: Women's Health, Vaginal Infections, Bacterial Vaginosis, Fungal Infections, Antibiotic-Free, Clinical Trials, Patents, Healthcare, Biotechnology, pHyph.